Compare Nu Holdings Ltd (NU) vs TG Therapeutics Inc (TGTX) Price & Performance

NU stock trades at $13.615, down 1.77% on the day, amid bearish technical signals but strong fundamentals. Revenue grew from $3.0B in 2022 to $10.63B in 2025, with net income turning positive to $2.87B. The company recently announced a Brazilian banking license acquisition (PYMNTS, 2026-07-22), supporting expansion. Analysts maintain a buy consensus with a $14.98 target, though recent earnings misses and competitive pressures pose headwinds.

Outlook: NU's robust growth trajectory and high ROE (30.04% as of 2025) offer upside, but technical weakness and Latin American market risks require caution. The Q2 2026 earnings report on August 13 (Defense World, 2026-08-12) is a key catalyst, with expectations of $0.1984 EPS. Investors should weigh strong profitability against bearish momentum and rising competition.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.